

Safety and Efficacy of DYNE-101 in Adults with DM1: Phase 1/2 ACHIEVE Trial Data

Richard H. Roxburgh,¹ Guillaume Bassez,² Jordi Diaz-Manera,³ Joost Kools,⁴ James B. Lilleker,⁵ Marika Pane,⁶ Benedikt Schoser,⁷ Christopher Turner,⁸ Chris Mix,⁹ Soma Ray,⁹ Baoguang Han,⁹ Wildon Farwell,⁹ Daniel Wolf,⁹ Valeria Sansone¹⁰

¹Neurogenetics Clinic Centre for Brain Research, University of Auckland, Auckland, NZ; ²Institut de Myologie, Paris, France; ³John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle-Upon-Tyne, UK; ⁴Radboud University Medical Center, Nijmegen, Netherlands; ⁵Muscle Disease Unit, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; ⁶Fondazione Policlinico Universitario A. Gemelli, Rome, Italy; ⁷Friedrich-Baur-Institute, Department of Neurology LMU Clinics, Ludwig-Maximilians University, Munich, Germany; ⁸University College London Hospitals, London, UK; ⁹Dyne Therapeutics, Inc., Waltham, MA, USA; ¹⁰Centro Clinico NEMO, University of Milan, Milan, Italy




Disclosures

- I have received travel compensation from Dyne to attend this congress.
- DYNE-101 is an investigational medicine being evaluated in the ongoing ACHIEVE trial and has not received approval by FDA, EMA, or any other regulatory authorities


Spliceopathy in DM1 Drives Multisystem Disease Manifestations

NORMAL SPLICING



Normal splicing leads to **appropriate protein synthesis**


DM1 SPLICEOPATHY




Disrupted splicing **impairs** normal protein synthesis

CONSEQUENCES OF SPLICEOPATHY

Myotonia and muscle weakness



Cardiac conduction complications



Pulmonary abnormalities




Cognitive impairment




Abnormal splicing in **multiple tissues** causes symptoms of DM1

FORCE™ Platform-based Oligonucleotide Therapeutics for Muscle Diseases



ASO, antisense oligonucleotide; Fab, antigen-binding fragment; siRNA, small interfering RNA; TfR1, transferrin receptor 1.
Adapted from Desjardins CA, et al. *Nucleic Acids Res* 2022;50(20):11401–11414 and Ohrt T, et al. *Nucleic Acids Res* 2006;34(5):1369.

DYNE-101 Targets Mutant Nuclear *DMPK* RNA



Phase 1/2 Clinical Trial to Evaluate DYNE-101 in Patients with DM1




Population	Primary Endpoints	Additional Endpoints	Stages of ACHIEVE
• Adult patients living with DM1 • Ages 18 to 49 years	• Safety and tolerability	• Pharmacokinetics • Change from baseline of: – Splicing – <i>DMPK</i> RNA expression – Multiple assessments of muscle strength and function – Patient-reported outcomes, including DM1-ACTIV^c and MDHI	• Multiple ascending dose (MAD): 24 weeks • Open-label extension (OLE): 24 weeks • Long-term extension (LTE): 96 weeks

Additional endpoints include select secondary and exploratory endpoints.
DM1-ACTIV^c, Myotonic Dystrophy type 1 Activity and participation scale; MDHI, Myotonic Dystrophy Health Index.
For more information visit the ACHIEVE clinical trial posting on [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT05481879) Identifier:NCT05481879 or [clinicaltrialsregister.eu](https://clinicaltrialsregister.eu/clinicaltrialsregister/eu/2022-000889-18) EudraCT Number:2022-000889-18.
Wolf D, et al. Poster presentation at the World Muscle Society Annual Congress, Prague, Czechia, October 8–12, 2024. Poster 221P.

ACHIEVE Trial Design – Multiple Ascending Dose (MAD)

Global, randomized, placebo-controlled study evaluating once monthly or less frequent administration of DYNE-101 in adult patients living with DM1



MAD Study Details

- IV administration of DYNE-101 or placebo every 4 weeks or every 8 weeks
- Muscle biopsies: Baseline, 12 weeks, 24 weeks
- Patients in MAD study escalated to highest tolerable dose in OLE and LTE

MAD, multiple ascending dose; Q4W, every 4 weeks dosing; Q8W, every 8 weeks dosing; TBD, to be determined.

Doses provided refer to ASO component of DYNE-101. Recovery cohort Q4W × 2 doses then placebo for the remainder of the 24W placebo-controlled period. Q8W with booster includes Q4W × 3 doses then Q8W dosing. Study protocol allows for dosing up to 10.2 mg/kg.

Wolf D, et al. Poster presentation at the World Muscle Society Annual Congress, Prague, Czechia, October 8–12, 2024. Poster 221P.

Baseline Participant Characteristics

Mean (SD) or n (%) ¹	1.8 mg/kg Q4W (N=16)*	3.4 mg/kg Q4W (N=16)*	5.4 mg/kg Q8W (N=8) [†]
Age (years)	34.6 (10.4)	34.3 (7.6)	39.6 (7.0)
Female n (%)	7 (43.8)	3 (18.8)	5 (62.5)
BMI (kg/m ²)	22.4 (5.3)	23.8 (3.8)	21.7 (2.7)
CASI	0.62 (0.26)	0.67 (0.20)	0.79 (0.14)
CTG Repeats	375 (217)	527 (241)	586 (294)
Video Hand Opening Time (sec) (middle finger)	11.2 (4.3)	8.0 (5.7)	10.1 (6.2)
Quantitative Muscle Testing Total (% predicted)	49.6 (10.9)	47.8 (10.6)	45.8 (16.1)
10-Meter Run/Walk Test (sec) ²	3.5 (0.8)	3.6 (0.7)	4.7 (2.1)
5 Times Sit to Stand (sec)	9.33 (2.02)	10.05 (3.03)	12.28 (5.96)
DM1-ACTIV ^c Total	43 (7)	42 (7)	44 (6)
MDHI Total	25 (20)	25 (20)	16 (9)

*Q4W, recovery, and placebo arms are reported together for baseline characteristics. [†]Q8W and placebo arms are reported together for baseline characteristics.

BMI, body mass index; CASI, composite alternative splicing index; MDHI, Myotonic Dystrophy Health Index; SD, standard deviation; sec, seconds.

1. Wolf D, et al. Poster presentation at the World Muscle Society Annual Congress, Prague, Czechia, October 8–12, 2024. Poster 221P; 2. Dyne Corporate presentation. September 2024.

DYNE-101 Safety Profile is Favorable to Date

Summary of Treatment-emergent Adverse Events (TEAEs)*1

TEAE Category	Participants with ≥1 TEAE – n (%)					
	1.8 mg/kg Q4W+Rec. N=16	3.4 mg/kg Q4W+Rec. N=16	3.4 mg/kg Q8W N=8	5.4 mg/kg Q8W N=8	6.8 mg/kg Q8W N=8	Overall (N=56)
Any TEAE	16 (100%)	16 (100%)	8 (100%)	8 (100%)	7 (88%)	55 (98%)
Any related TEAE	8 (50%)	8 (50%)	2 (25%)	3 (38%)	5 (63%)	26 (46%)
Any serious TEAE	4 (25%)	0	1 (13%)	0	0	5 (9%)

Most TEAEs Were Mild or Moderate in Intensity¹

- **6 serious TEAEs unrelated to study drug**
 - Atrioventricular block first degree (1)[†]
 - Pneumonia (2 events in same participant)
 - Pulmonary embolism (1)[‡]
 - Hyponatremia (1)
 - Influenza (1)
- **Most common TEAEs (≥20% participant incidence)[§]**
 - Nasopharyngitis (32%)
 - Procedural pain (29%)
 - Infusion-related reaction (21%)

Additional Safety Data¹

- **Liver enzyme elevations have been observed in a minority of participants**
 - No impact on liver function (bilirubin or coagulation)
 - Interpretation is complicated by underlying disease and elevated baseline values up to ~2.5 × greater than the upper limit of normal
- **No participants have demonstrated persistent related anemia or thrombocytopenia**
- **There have been no serious related TEAEs, and no TEAEs leading to withdrawal or death**

~680 doses administered to date representing over 55 patient-years of follow-up*2


*Data as of August 20, 2024. [†]Transient worsening of atrioventricular (AV) block in a participant with ongoing medical history of first-degree AV block; [‡]Attributed to risk factors for pulmonary embolism; [§] All cohorts combined, preferred terms are reported. Rec, recovery.
1. Wolf D, et al. Poster presentation at the World Muscle Society Annual Congress, Prague, Czechia, October 8–12, 2024. Poster 221P; 2. Dyne Corporate presentation. September 2024.

Composite Alternative Splicing Index is a Prognostic Biomarker of Functional Outcomes in DM1


CASI quantifies RNA missplicing across a panel of 22 genes implicated in the pathophysiology of DM1¹⁻⁴

Role in DM1	Number of Genes
Muscle weakness and/or altered contraction and relaxation ^{1,2}	8
Aberrant mRNA splicing ^{1,2}	2
Insulin resistance ^{1,2}	1
Undefined, regulated by MBNL ^{1,5}	11

Natural history data support a strong correlation between CASI and muscle function (N=95)⁴




Worsening in CASI is observed in as little as 3 months in the natural history cohort (N=35)^{*4}




^{*}Data represent mean $\pm$ standard deviation; ^{***}p<0.001 by paired t-test.
¹. Wang W. 2017. University of Rochester School of Medicine and Dentistry PhD thesis. Available at <http://hdl.handle.net/1802/32572> (accessed August 2024); ². López-Martínez A, et al. *Genes (Base)*. 2020;11:1109; ³. Mikhail AI, et al. *Trends Mol Med* 2023;29:512–529; ⁴. Provenzano M, et al. *bioRxiv*. 2024. Available at: <https://www.biorxiv.org/content/10.1101/2024.07.10.602610v1> (accessed August 2024); ⁵. Gene functions from AmiGO 2. Available at: <https://amigo.geneontology.org/amigo> (accessed August 2024).

Monthly Dosing of DYNE-101 Demonstrated Dose-dependent Delivery and Consistent Splicing Correction at 3 Months



One post-baseline sample in 3.4 mg/kg Q4W treatment group not included within splicing assay as the sample did not meet QC criteria.
SEM, standard error of mean.
Wolf D, et al. Poster presentation at the World Muscle Society Annual Congress, Prague, Czechia, October 8–12, 2024. Poster 221P.

Treatment with DYNE-101 Resulted in Continued Improvement in Functional Myotonia at 6 and 12 Months




*Middle finger (sec) is the average of all myotonia trials for an individual participant in ACHIEVE.
Note: Placebo group includes 12 participants at Day 85 and 8 participants at Day 169. Mean percent change from baseline for placebo group are based on baseline values from 12 patients.
sec, seconds; SE, standard error.
1. Wolf D, et al. Poster presentation at the World Muscle Society Annual Congress, Prague, Czechia, October 8–12, 2024. Poster 221P; 2. Dyne Corporate presentation. September 2024.

DYNE-101 Demonstrated Improvement in Muscle Strength


Measured by Quantitative Muscle testing (QMT)

QMT Total Score



Note: Mean percent change from baseline for placebo group is based on baseline values from 12 patients. Placebo group includes 12 participants at Day 85 and 8 participants at Day 169. Wolf D, et al. Poster presentation at the World Muscle Society Annual Congress, Prague, Czechia, October 8–12, 2024. Poster 221P.

DYNE-101 Demonstrated Early and Sustained Potential Benefit Across Multiple Timed Function Tests




Note: Mean percent change from baseline for placebo group is based on baseline values from 12 patients. Placebo group includes 12 participants at Day 85 and 8 participants at Day 169.


1. Dyne Corporate presentation. September 2024; 2. Wolf D, et al. Poster presentation at the World Muscle Society Annual Congress, Prague, Czechia, October 8–12, 2024. Poster 221P.

DYNE-101 Demonstrated Clinical Benefit Based on Well-validated PROs

DM1-ACTIV^c



Improved MDHI Total Score



PROs, including DM1-ACTIV^c and MDHI collected at baseline, Day 169 and Day 337.
Wolf D, et al. Poster presentation at the World Muscle Society Annual Congress, Prague, Czechia, October 8–12, 2024. Poster 221P.

Summary

- **DYNE-101** is designed to target mutant **nuclear DMPK** RNA with the goal of **correcting the abnormal splicing** to improve the **multisystem disease manifestations** of **DM1**^{1,2}
- The Phase 1/2 **ACHIEVE** trial is an ongoing, randomized, placebo-controlled global trial of DYNE-101 in adults with DM1 aged 18–49 years. In the MAD portion of ACHIEVE:³
 - DYNE-101 was **well tolerated**
 - DYNE-101 was **delivered** effectively to **skeletal muscle**
 - DYNE-101 showed **dose-dependent** and **consistent splicing correction**
 - DYNE-101 led to **early improvements** in **multiple functional endpoints**
 - DYNE-101 led to **improvements** in well validated **patient-reported outcomes**

Acknowledgements



ACHIEVE participants and their families

